Suzetrigine Versus Standard Analgesia After Skin Cancer Surgery

ClinicalTrials.gov ID: NCT07843134

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07843134. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Non-Opioid Postoperative Pain Management in Skin Cancer Surgery: A Randomized Trial of Suzetrigine Versus Standard Analgesia in Minnesota

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized clinical trial will compare suzetrigine with standard analgesia for postoperative pain management after skin cancer surgery. Adults undergoing Mohs micrographic surgery or wide local excision for cutaneous malignancy or a skin-cancer precursor lesion of the head and neck will be randomized to suzetrigine monotherapy or scheduled acetaminophen plus ibuprofen for 72 hours after surgery. The study uses a double-blind, double-dummy design, and breakthrough oxycodone may be prescribed in either arm on request after same-day clinical assessment. The primary objective is to determine whether suzetrigine controls acute postoperative pain as well as scheduled acetaminophen plus ibuprofen during the first 24 hours after the first dose. Secondary outcomes include rescue opioid consumption, pain through 48 and 72 hours, satisfaction with pain control, functional recovery, adverse events, surgical bleeding, wound-healing complications, and blinding integrity.

Study identification

NCT ID: NCT07843134
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: University of Minnesota; Other
Enrollment: 230 participants

Conditions and interventions

Conditions

Interventions

Suzetrigine Drug
Acetaminophen Plus Ibuprofen Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 1, 2027 (Estimated)
Primary completion: Apr 30, 2029 (Estimated)
Completion: Jul 30, 2029 (Estimated)
Last update posted: Sep 25, 2026

2027 – 2029

United States locations

U.S. sites: 3
U.S. states: 1
U.S. cities: 3

Facility	City	State	ZIP	Site status
M Health Fairview Clinic - Maple Grove	Maple Grove	Minnesota	55369	—
M Health Fairview Clinics and Surgery Center	Minneapolis	Minnesota	55455	—
M Health Fairview Clinic - Wyoming	Wyoming	Minnesota	55092	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07843134, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 25, 2026 · Synced Nov 13, 2026